PATENT CLAIM ANALYSIS

Application Number: 16090415
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "571000"]

Abstract:
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Claim (Index 5):
Elafibranor for use according to any one of the preceding claims, wherein the cholestatic disease is selected in the group consisting of Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy, Progressive Familial Intrahepatic Cholestasis, Biliary atresia, Cholelithiasis, Infectious Cholangitis, Cholangitis associated with Langerhans cell histiocytosis, Alagille syndrome, Nonsyndromic ductal paucity, Drug-induced cholestasis, and Total parenteral nutrition\u2014associated cholestasis.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.06061
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15496875', '16032380', '16030141', '15720849', '15903279']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7949787696532632
- 35 USC 102 Novelty (BERT): 0.5398833994975345
- Combined Prediction Score: 0.7694692326376904
- Mean Citation Score: 335.005982
- Max Citation Score: 368.9588
- Similarity Product: 194.59116444530488

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test